Rectal Cancer Clinical Trial
— CCRPWAROfficial title:
"Cross" Closure for Reconstructing the Perineal Wound of Abdominoperineal Resection in Rectal and Anal Cancer Patients: a Multi-center, Randomized, Open-Label, Positive, Parallel Controlled Clinical Trial
How to reduce the complications of perineal wound after abdominoperineal resection (APR) has always been a hot topic in the medical field.To reduce the complications of perineal wound and the primary healing of perineal wound must meet the two principles of "unobstructed drainage" and " reduced tension closure".This concept is similar to the concepts of closure of enterostomy in rectal cancer patients. It was reported that use of cross-stitch closure can significantly reduce complications of closure of enterostomy. So the investigator ever used the "cross" closure to reconstruct the perineal wound of APR, which was really decrease the complications of perineal wound. However, more clinical trails was needed to confirm the conclusion.
Status | Not yet recruiting |
Enrollment | 346 |
Est. completion date | December 20, 2020 |
Est. primary completion date | November 20, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility |
Inclusion Criteria: 1. Age: 18-75 years old; 2. ECOG performance status: 0-2; 3. Histologically confirmed rectal cancer or anal canal cancer; 4. Completely resected the primary tumor; 5. No evidence of distant metastasis; 6. Tolerable general anesthesia; 7. Total radiation dose of 45-50 Gy needed if the patient needs to receive routine segmental radiotherapy; 8. Provision of written informed consent. Exclusion Criteria: 1. Emergency surgery required when the patients combined with acute ileus, perforation and hemorrhage; 2. Extralevator abdominoperineal resection needed; 3. American Society of Anesthesiologists (ASA) IV or V; 4. Combined with other tumors; 5. Severe mental illness; (7)Serious cardiovascular disease, uncontrolled infections, or other serious uncontrolled concomitant disease; (8)Expectation of lateral lymph node dissection preoperatively |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Sixth Affiliated Hospital, Sun Yat-sen University | Cancer Institute and Hospital, Chinese Academy of Medical Sciences, First Affiliated Hospital of Jinan University, First Affiliated Hospital, Sun Yat-Sen University, Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou First People's Hospital, Jieyang People's Hospital, Meizhou People's Hospital, Second Affiliated Hospital of Guangzhou Medical University, Southern Medical University, China, The Affiliated Hospital of Guangdong Medical College, The First Affiliated Hospital of Guangzhou Medical University, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Complication rate of perineal wound | the complications of perineal wound are include wound infection, wound effusion, wound liquefaction, wound dehiscence, seroma or hematoma ,delayed wound healing, presacral or perineal abscess, perineal or pelvic floor hernia | Within 30 days after operation | |
Secondary | Primary wound healing rate | the Primary wound healing rate within 30 days after operation | Within 30 days after operation | |
Secondary | CTCAE grade for complications of perineal wound | the CTCAE grade for complications of perineal wound within 30 days after surgery | Within 30 days after surgery | |
Secondary | The incidence of each complication of perineal wound | The incidence of each complication of perineal wound within 30 days after surgery | Within 30 days after surgery | |
Secondary | The rate of reoperation | The rate of reoperation within 30 days after surgery | Within 30 days after surgery | |
Secondary | The volumes of presacral drainage | The volumes of presacral drainage within 3, 5, 7 days after surgery | Within 3, 5, 7 days after surgery | |
Secondary | The volumes of presacral residual cavity hydrops | The volumes of presacral residual cavity hydrops within 3 and 7 days postoperatively | 3 and 7 days postoperatively | |
Secondary | The times of dressing change of perineal wound | The times of dressing change of perineal wound within 3, 5, 7 days after surgery | Within 3, 5, 7 days after surgery | |
Secondary | Removal time of presacral drainage tube | Removal time of presacral drainage tube within 30 days after surgery | Within 30 days after surgery | |
Secondary | Scar scores for perineal wound and evaluation of patients' overall satisfaction | Scar scores for perineal wound and evaluation of patients' overall satisfaction within 30 days after surgery | Within 30 days after surgery | |
Secondary | Hospital stay after surgery | Hospital stay after surgery within 30 days after surgery | Within 30 days after surgery | |
Secondary | The operation time | The operation time | Intraoperatively |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06380101 -
Evaluating a Nonessential Amino Acid Restriction (NEAAR) Medical Food With Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer (LARC)
|
N/A | |
Active, not recruiting |
NCT05551052 -
CRC Detection Reliable Assessment With Blood
|
||
Recruiting |
NCT04323722 -
Impact of Bladder Depletion on Mesorectal Movements During Radiotherapy in Rectal Cancer
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04088955 -
A Digimed Oncology PharmacoTherapy Registry
|
||
Active, not recruiting |
NCT01347697 -
Collagen Implant (Biological Mesh) Versus GM Flap for Reconstruction of Pelvic Floor After ELAPE in Rectal Cancer
|
N/A | |
Recruiting |
NCT04495088 -
Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer
|
Phase 3 | |
Withdrawn |
NCT03007771 -
Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia
|
Phase 1 | |
Terminated |
NCT01347645 -
Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT03520088 -
PROSPECTIVE CONTROLLED AND RANDOMIZED STUDY OF THE GENITOURINARY FUNCTION AFTER RECTAL CANCER SURGERY IN RELATION TO THE DISSECTION OF THE INFERIOR MESENTERIC VESSELS
|
N/A | |
Recruiting |
NCT05556473 -
F-Tryptophan PET/CT in Human Cancers
|
Phase 1 | |
Recruiting |
NCT04749381 -
The Role of TCM on ERAS of Rectal Cancer Patients
|
Phase 2 | |
Enrolling by invitation |
NCT05028192 -
Mitochondria Preservation by Exercise Training: a Targeted Therapy for Cancer and Chemotherapy-induced Cachexia
|
||
Recruiting |
NCT03283540 -
Transanal Total Mesorectal Excision for Rectal Cancer on Anal Physiology + Fecal Incontinence
|
||
Completed |
NCT04534309 -
Behavioral Weight Loss Program for Cancer Survivors in Maryland
|
N/A | |
Recruiting |
NCT05914766 -
An Informational and Supportive Care Intervention for Patients With Locally Advanced Rectal Cancer
|
N/A | |
Recruiting |
NCT04852653 -
A Prospective Feasibility Study Evaluating Extracellular Vesicles Obtained by Liquid Biopsy for Neoadjuvant Treatment Response Assessment in Rectal Cancer
|
||
Recruiting |
NCT03190941 -
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
|
Phase 1/Phase 2 | |
Terminated |
NCT02933944 -
Exploratory Study of TG02-treatment as Monotherapy or in Combination With Pembrolizumab to Assess Safety and Immune Activation in Patients With Locally Advanced Primary and Recurrent Oncogenic RAS Exon 2 Mutant Colorectal Cancer
|
Phase 1 | |
Completed |
NCT02810652 -
Perioperative Geriatrics Intervention for Older Cancer Patients Undergoing Surgical Resection
|
N/A |